N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=200 Standardization of Surgery on the Pancreatic Cancer
Pancreatic Cancer
Primary: Survival — 37; 31 participants
N/A N=1 Stereotactic Radiation to Decrease Pancreatic Secretions
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 3 N=170 Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
Phase 3 N=168 Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
N/A N=190 Antibiotic Irrigation for Pancreatoduodenectomy
Surgery · Infection
Primary: The Number of Patients With Infections — 11; 10 Participants
Early Phase 1 N=11 Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 4 N=48 Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies
Pancreatectomy
Primary: Overall Pain in Postoperative Period — 1.6; 2.7 score on a scale — p=0.1459
Phase 2 N=35 Perioperative Therapy for Resectable Pancreatic Cancer
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
N/A N=5 Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients
Obesity
Primary: Fat Absorption — 60.6 g/d — p=<0.05
Phase 2 N=114 A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Pancreatic Leak · Pancreatic Fistula · Pancreaticoduodenal; Fistula
Primary: Combined Clinically Significant Postoperative Pancreatic Fistula and Intra-abdominal Abscess — 8 Participants
N/A N=77 Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer
Pancreatic Carcinoma
Primary: Percentage of Patients Discharged by Post-operative Day 5 — 5; 28 Participants
Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
Phase 4 N=50 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
Pancreatic Cancer · Bile Duct Cancer
Primary: Postoperative Infectious Complication — 7; 15 participants — p=<0.05
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
N/A N=10 Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes
Hyperinsulinism · Diabetes · Pancreatic Diseases
Primary: Mean Plasma Glucose Level. — 149.666118; 162.574753 mg/dL
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
Phase 2 N=32 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
Resectable Pancreatic Cancer · Unresectable Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235
Phase 3 N=54 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
Chronic Pancreatitis · Pancreatectomy · Pancreatic Exocrine Insufficiency
Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001
Phase 2 N=39 Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Pancreatic Cancer
Primary: Overall Survival at 18 Months — 63 percentage of participants
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 3 N=439 Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Pancreatic Cancer
Primary: To Compare 60-day ≥Grade 3 Pancreatic Complication Rates (Fistula, Leak, and Abscess) as Defined by the MSKCC Surgical Secondary Events System Between Patients Who…
Phase 2 N=48 Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 2 N=25 Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Chronic Pancreatitis · Insulin Resistance · Normal or Mildly Abnormal Stool Fat Levels
Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants
Phase 3 N=133 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Pancreatic Cancer
Primary: Number of Incidences of Grade 3 or Greater Complications — 0; 0 Number of complications